Scinai Immunotherapeutics Ltd. annual report, Q4 FY2020

Filing and reporting period

The supplied filing is BiondVax Pharmaceuticals Ltd.’s Form 20-F annual report for the fiscal year ended December 31, 2020, filed May 13, 2021. It is not a Scinai Immunotherapeutics filing, and it reports annual—not standalone Q4—results. The company reports under IFRS as issued by the IASB; U.S. dollar figures below are convenience translations.

Business context and key financial metrics

BiondVax is an Israel-based development-stage biopharmaceutical company. Its M-001 universal influenza vaccine failed to meet primary and secondary efficacy endpoints in its Phase 3 trial announced October 23, 2020, although the primary safety endpoint was met. At year-end, it had no product candidates in active development and no revenue.

FY2020 operating cash outflow was $22.6 million; investing cash outflow was $1.8 million and financing cash inflow was $4.3 million. Cash fell about 87% year over year. No revenue-based margins are meaningful because the company had no revenue.

At December 31, 2020, total assets were $17.7 million, total liabilities $22.2 million, and shareholders’ equity was negative $4.5 million. The filing reports negative working capital of approximately $16.8 million and an accumulated deficit of approximately $101.0 million. The EIB loan was originally €24 million; its reported year-end carrying amount was $18.8 million, while the filing gives a nominal outstanding principal amount of $29.4 million. The EIB has a first-ranking floating charge over substantially all company assets, with stated exclusions.

Material changes versus the prior comparable period

• R&D expense declined about 25%, mainly because Phase 3 trial costs fell by NIS 17.1 million.
• General and administrative expense rose about 72%, including increased share-based compensation and directors’ and officers’ insurance costs.
• The reported net loss narrowed sharply, primarily because of $23.5 million of other income associated with remeasurement of EIB and IIA liabilities after management estimated there would likely be no future M-001 sales or related royalties. This was not operating revenue.
• Cash and cash equivalents decreased from $22.5 million to $2.9 million, while the M-001 trial failure left the company without an active product-development program.

Outlook, risks and unusual items

Management was evaluating strategic alternatives, including licensing or acquiring assets, collaborations, joint ventures, mergers, or monetization of existing assets. The filing provides no committed product pipeline, revenue outlook, or financial guidance. Management warned that failure to execute a strategy or obtain funding could force the company to curtail operations or wind down.

• Funding and liquidity: The company expected ongoing losses and negative cash flow and said additional financing or a strategic transaction would be needed. It reported a February 2021 offering that raised approximately $13.8 million gross and $12.8 million net. The filing’s liquidity statements differ: one says resources, including that offering, were expected to fund at least 24 months; the audited note says management believed year-end resources would support at least 12 months.
• EIB financing: The EIB stated in January 2021 that the Phase 3 failure alone would not trigger prepayment, but reserved its other rights. The loan may be accelerated in certain default or other circumstances, and enforcement against pledged assets could threaten continued operations.
• Asset valuation: No impairment of non-financial assets was recorded. The auditor identified valuation of factory leasehold assets as a critical audit matter because recoverability estimates relied on uncertain future cash flows from alternative uses after the trial failure.
• Controls: Management and the auditor concluded internal control over financial reporting was ineffective at year-end due to material weaknesses involving control documentation and timeliness, and evidence of management review. The auditor issued an adverse opinion on internal control, while issuing an unqualified opinion on the IFRS financial statements.
• Other risks: The filing highlights potential inability to secure partners or suitable assets, dilution from future financing, possible delisting, COVID-19-related uncertainty, and Israeli operating and regulatory risks. Management said the pandemic had not meaningfully affected the Phase 3 trial’s timing or conduct.

Important facts for investors to verify

• Confirm the issuer: this is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.; confirm the relevant reporting period, since quarterly Q4 figures are not separately provided.
• Review subsequent filings for actual cash runway, use of the February 2021 offering proceeds, and any later financing or strategic transaction.
• Reconcile the EIB loan’s nominal principal, reported carrying value, repayment schedule, collateral, and any subsequent waivers or default notices.
• Assess the basis for the factory’s carrying value and whether later impairment testing resulted in a write-down.
• Track remediation of the disclosed material weaknesses and verify whether controls were later found effective.